Table 4.
Characteristics | Disease-free survival | Overall survival | ||||
---|---|---|---|---|---|---|
HR | 95% CI | p | HR | 95% CI | p | |
Univariate analysis | ||||||
Age | 2.603 | 1.321–5.166 | 0.006 | 2.777 | 1.348–5.718 | 0.006 |
FIGO stage | 2.956 | 1.454–6.011 | 0.003 | 3.420 | 1.600–7.312 | 0.002 |
Differentiation | 5.221 | 2.628–10.375 | 2.39E−6 | 5.516 | 2.676–11.372 | 3.72E−6 |
Myometrial invasion | 4.911 | 2.477–9.738 | 5.17E−6 | 5.411 | 2.635–11.112 | 4.25E−6 |
LVSI | 6.352 | 2.940–13.722 | 2.55E−6 | 6.675 | 3.046–14.627 | 2.11E−6 |
LNM | 14.51 | 6.994–30.103 | 6.79E−13 | 15.02 | 6.964–32.384 | 4.84E−12 |
Cervical stromal involvement | 1.589 | 0.797–3.170 | 0.188 | 1.932 | 0.942–3.959 | 0.072 |
BKCa expression | 1.121 | 0.558–2.253 | 0.749 | 1.123 | 0.541–2.331 | 0.756 |
ERK1/2 expression | 0.594 | 0.300–1.175 | 0.134 | 0.546 | 0.267–1.120 | 0.099 |
p-ERK1/2 expression | 4.149 | 1.800–9.563 | 0.001 | 4.358 | 1.781–10.664 | 0.001 |
Multivariate analysis | ||||||
Age | 1.717 | 0.842–3.503 | 0.137 | 1.912 | 0.909–4.025 | 0.088 |
FIGO stage | 1.268 | 0.538–2.986 | 0.587 | 1.607 | 0.648–3.983 | 0.306 |
Differentiation | 3.111 | 1.413–6.851 | 0.005 | 3.494 | 1.520–8.034 | 0.003 |
Myometrial invasion | 3.096 | 1.430–6.703 | 0.004 | 3.648 | 1.642–8.106 | 0.001 |
LVSI | 0.503 | 0.154–1.647 | 0.256 | 0.635 | 0.196–2.050 | 0.447 |
LNM | 5.008 | 1.513–16.573 | 0.008 | 3.832 | 1.145–12.826 | 0.029 |
p-ERK1/2 expression | 3.912 | 1.542–9.927 | 0.004 | 3.796 | 1.415–10.180 | 0.008 |
FIGO International Federation of Gynecology and Obstetrics, LVSI lymph vascular space invasion, LNM lymph node metastasis, HR hazard ratio, 95% CI, 95% confidence interval